General Information of the Drug (ID: M6APDG03167)
Name
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
Synonyms
CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H7Cl4NO2
InChI
1S/C15H7Cl4NO2/c16-10-8-9(11(17)13(19)12(10)18)15(22)20(14(8)21)6-7-4-2-1-3-5-7/h1-5H,6H2
InChIKey
MQFQHWBPMPPVNJ-UHFFFAOYSA-N
PubChem CID
983732
TTD Drug ID
D01HDD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Oxysterols receptor LXR-alpha (NR1H3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). [1], [2]
References
Ref 1 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021 Jan 8;12(1):177. doi: 10.1038/s41467-020-20379-7.
Ref 2 Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. doi: 10.1016/j.bmcl.2007.04.090. Epub 2007 Apr 30.